Document Detail

Switching from natalizumab to fingolimod: an observational study.
MedLine Citation:
PMID:  23336398     Owner:  NLM     Status:  Publisher    
BACKGROUND: Multiple sclerosis patients who discontinue using natalizumab are at risk of a rebound in disease activity. However, the optimal alternative therapy is not currently known. AIMS OF THE STUDY: We report on clinical and MRI data and patient safety in a group of relapsing-remitting multiple sclerosis patients who tested seropositive for the JC virus and who have switched from natalizumab to fingolimod because of concerns regarding PML risks. METHODS: The test for JC virus antibodies was performed in 18 relapsing-remitting multiple sclerosis patients who were being treated with natalizumab for more than 1 year. Eight seropositive patients switched to fingolimod while the seronegative patients continued with natalizumab. RESULTS: After switching to fingolimod, five of eight patients (63%) experienced clinical relapses, and MRI activity was detected in six of eight patients (75%). Neither clinical relapses nor MRI activity was observed in the patients who continued with natalizumab. No serious adverse effects were detected. CONCLUSIONS: Natalizumab is an effective treatment for relapsing-remitting multiple sclerosis, but its discontinuation continues to be a complex problem. All of the therapies tried thus far, including fingolimod, have been unable to control the reactivation of the disease. Further studies addressing alternative therapies after natalizumab discontinuation are necessary.
A P Sempere; P Martín-Medina; L Berenguer-Ruiz; N Pérez-Carmona; R Sanchez-Perez; J Polache-Vengud; E Feliu-Rey
Related Documents :
23326268 - Murine typhus: an important consideration for the nonspecific febrile illness.
23536408 - Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry to ...
24447838 - In-center hemodialysis attendance: patient perceptions of risks, barriers, and recommen...
21798528 - More dead than dead: perceptions of persons in the persistent vegetative state.
24982778 - What is the feasibility of switching to 200iu onabotulinumtoxina in patients with detru...
10966498 - Evidence in vivo showing increase of baseline nitric oxide generation and impairment of...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-22
Journal Detail:
Title:  Acta neurologica Scandinavica     Volume:  -     ISSN:  1600-0404     ISO Abbreviation:  Acta Neurol. Scand.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370336     Medline TA:  Acta Neurol Scand     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2013 John Wiley & Sons A/S.
Neurology Department, Hospital General Universitario de Alicante, Alicante, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Real-time detection of G protein activation using monomolecular G? FRET sensors.
Next Document:  Physical activity intensity and subclinical atherosclerosis in Danish adolescents: the European Yout...